Is It Too Late to Buy Moderna Stock After Its 127% Surge?
Is It Too Late to Buy Moderna Stock After Its 127% Surge?
Thomas Niel, The Motley FoolSun, August 30, 2026 at 5:05 PM UTC
0
Image source: Getty Images.Key Points -
Moderna has made an incredible comeback, surging sixfold over the past year and by around 127% over the past few weeks.
The MRNA vaccine company recently announced promising news that could have major implications for its pivot toward oncology.
Yet while the pandemic-era darling has made a comeback, shares could pull back as the market determines a value for its future potential.
10 stocks we like better than Moderna ›
Moderna(NASDAQ: MRNA) shares have made an incredible comeback this year. Up by nearly sixfold over the past 12 months, the stock, formerly one of the top COVID-19 vaccine plays, has surged thanks to developments with the non-COVID aspects of its pipeline.
The most recent surge, sending the stock up around 127% in a matter of weeks, stems from a breakthrough for the biotech company. Now, the question is whether Moderna can hold on to, much less add to, these latest gains.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again.In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Moderna and its cancer vaccine super rally
Post-pandemic, investors bailed on what was once one of the most-followed biotech stocks amid pessimism about the company's ability to further monetize its mRNA technology. But then, as the company made further progress with its Intismeran Autogene vaccine candidate, bearishness shifted back to bullishness, turning Moderna into an incredible comeback story.
Then, on Aug. 19, Moderna, along with pharmaceutical company Merck(NYSE: MRK), announced positive top-line results for its phase 3 INTerpath-001 trial. This trial involved giving Stage IIB-IV melanoma patients a combination of Intismeran Autogene and Merck's Keytruda.
Separating substance from hype
On one hand, Moderna's super rally on the INTerpath-001 news made sense because this study strongly suggests that Moderna can succeed in employing its mRNA technology to develop effective oncology treatments. Given the massive total addressable market for such treatments, it's logical for the market to rerate shares significantly.
Then again, while the prospect of personalized cancer vaccines represents a serious game changer for medicine, keep in mind two things. First, the extent of Moderna's latest rally was likely boosted by a short squeeze. Shares initially surged by as much as 175% on the news and have since pulled back. A further cooldown in excitement could continue playing out.
Second, while by all means a likely game changer for Moderna, commercialization of these oncology MRNA products remains years away. With a nearly $60 billion market capitalization, estimated 2026 revenue of just $2.1 billion, and a stock price around $140 to $145 per share against forecast losses of $8.55 per share this year, future potential with oncology appears heavily baked in.
Advertisement
Even if bullish on Moderna's comeback catalyst, you may want to wait for further weakness before buying.
Should you buy stock in Moderna right now?
Before you buy stock in Moderna, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Moderna wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $440,710!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,335,252!*
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 30, 2026.
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck and Moderna. The Motley Fool has a disclosure policy.
Source: “AOL Money”
